| Tbio | TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 |
May be an important signaling intermediate between TGFB receptors and MAP3K7/TAK1. May play an important role in mammalian embryogenesis.
The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Polycystic ovary syndrome | 348 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| juvenile dermatomyositis | 1147 | 2.8e-11 |
| osteosarcoma | 7766 | 1.8e-06 |
| glioblastoma | 5635 | 5.5e-06 |
| atypical teratoid / rhabdoid tumor | 4971 | 3.7e-05 |
| medulloblastoma, large-cell | 6086 | 1.5e-04 |
| adult high grade glioma | 3701 | 7.9e-04 |
| non primary Sjogren syndrome sicca | 861 | 1.4e-02 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | -1.400 | 7.9e-04 |
| atypical teratoid / rhabdoid tumor | -1.300 | 3.7e-05 |
| glioblastoma | -1.500 | 5.5e-06 |
| juvenile dermatomyositis | -1.073 | 2.8e-11 |
| medulloblastoma, large-cell | -1.300 | 1.5e-04 |
| non primary Sjogren syndrome sicca | 1.200 | 1.4e-02 |
| osteosarcoma | -1.180 | 1.8e-06 |
MAAQRRSLLQSEQQPSWTDDLPLCHLSGVGSASNRSYSADGKGTESHPPEDSWLKFRSENNCFLYGVFNG 1 - 70 YDGNRVTNFVAQRLSAELLLGQLNAEHAEADVRRVLLQAFDVVERSFLESIDDALAEKASLQSQLPEGVP 71 - 140 QHQLPPQYQKILERLKTLEREISGGAMAVVAVLLNNKLYVANVGTNRALLCKSTVDGLQVTQLNVDHTTE 141 - 210 NEDELFRLSQLGLDAGKIKQVGIICGQESTRRIGDYKVKYGYTDIDLLSAAKSKPIIAEPEIHGAQPLDG 211 - 280 VTGFLVLMSEGLYKALEAAHGPGQANQEIAAMIDTEFAKQTSLDAVAQAVVDRVKRIHSDTFASGGERAR 281 - 350 FCPRHEDMTLLVRNFGYPLGEMSQPTPSPAPAAGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMVNG 351 - 420 AHSASTLDEATPTLTNQSPTLTLQSTNTHTQSSSSSSDGGLFRSRPAHSLPPGEDGRVEPYVDFAEFYRL 421 - 490 WSVDHGEQSVVTAP 491 - 504 //
